Work

Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.tps288

Authors: Neeraj Agarwal, Michael Thomas Schweizer, Elena Castro, Arun Azad, Daniel J. George, Jayeta Chakrabarti, Sujata Narayanan, Yiyun Tang, Karim Fizazi

Institutions: University of Utah, Huntsman Cancer Institute, University of Washington, Fred Hutch Cancer Center, Hospital Universitario 12 De Octubre, Peter MacCallum Cancer Centre, Duke University, Duke Cancer Institute, Pfizer (United States), Université Paris-Saclay, Institut Gustave Roussy

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4407699752

Cites:

Cited by: 5

Related to: 10